Discovery of thieno2,3- d pyrimidine-based dual Aurora B/VEGFR-2 inhibitors with potent anticancer activity: molecular docking, mechanistic studies, and in vivo validation in a breast cancer model | Synapse
April 24, 2026RSC Advances2 citationsOpen Access
Discovery of thieno2,3- d pyrimidine-based dual Aurora B/VEGFR-2 inhibitors with potent anticancer activity: molecular docking, mechanistic studies, and in vivo validation in a breast cancer model
The aim is to discover new dual inhibitors targeting Aurora B and VEGFR-2 with enhanced anticancer properties.
Molecular docking to analyze interactions between compounds and targets.
In vitro and in vivo studies to evaluate the efficacy of the inhibitors in breast cancer models.
The dual inhibitors showed significant anticancer activity in vitro and in vivo.
Enhanced inhibition of cancer cell proliferation and tumor growth compared to existing treatments.
Abstract
Breast cancer continues to be the most common malignancy in women and a major contributor of cancer-related mortality, emphasizing the need for novel therapeutic agents.